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Background: Although disease-specific health status measures are available for ankylosing spondyli-
tis (AS), no instrument exists for assessing quality of life (QoL) in the condition.
Objective: To produce an AS-specific QoL measure that would be relevant and acceptable to respond-
ents, valid, and reliable.
Methods: The ASQoL employs the needs-based model of QoL and was developed in parallel in the UK
and the Netherlands (NL). Content was derived from interviews with patients in each country. Face and
content validity were assessed through patient field test interviews (UK and NL). A postal survey in the
UK produced a more efficient version of the ASQoL, which was tested for scaling properties, reliability,
internal consistency, and validity in a further postal survey in each country.
Results: A 41 item questionnaire was derived from interview transcripts. Field testing interviews con-
firmed acceptability. Rasch analysis of data from the first survey (n=121) produced a 26 item question-
naire. Rasch analysis of data from the second survey (UK: n=164; NL: n=154) showed some item
misfit, but showed that items formed a hierarchical order and were stable over time. Problematic items
were removed giving an 18 item scale. Both language versions had excellent internal consistency
(α=0.89–0.91), test-retest reliability (rs=0.92 UK and rs=0.91 NL), and validity.
Conclusions: The ASQoL provides a valuable tool for assessing the impact of interventions for AS and
for evaluating models of service delivery. It is well accepted by patients, taking about four minutes to
complete, and has excellent scaling and psychometric properties.
Ankylosing spondylitis (AS) is a chronic inflammatoryrheumatic condition affecting the sacroiliac joints, thespinal column to a varying degree, and to a smaller
extent the peripheral joints. Patients have pain, morning stiff-
ness, and disability which increases with duration of disease.
A number of patients also experience extra-spinal and extra-
articular manifestations as acute anterior uveitis and inflam-
matory bowel disease.1 Population studies report a prevalence
of AS of between 0.5% and 1.6% and it is more commonly
found in men than women.2 3 The pattern and rate of disease
progression are variable but may be independent of disease
duration.4 Although major advances in the understanding of
the disease pathogenesis have occurred in recent years, the
optimal strategy for treatment is still unknown. Disease onset
is generally in late adolescence or early adulthood and, conse-
quently, the effects are present for most of the patient’s life.
Progression may continue through what should be economi-
cally active years.5 Chamberlain reported that two thirds of
male patients have difficulty at work, one third have social
problems, and up to two thirds report having difficulty with
sexual activity.6 Reactive depression and frustration are noted,
together with impaired self esteem and social skills.6 Energy
related problems are also widely reported.6 All these features
denote significant effects of the disease on lifestyle.
There is a growing interest in the assessment of quality of
life (QoL), particularly in chronic disabling conditions. It is
becoming relatively common to measure QoL in studies
designed to assess the impact of new pharmaceutical products
or to compare different treatment regimens. Although the con-
cept has existed for many years, it is only within the past few
decades that attempts have been made to operationalise QoL
into a construct that can be measured in a meaningful way.7
Instruments currently available for use with patients with
AS focus predominantly on symptoms (impairment) or func-
tioning (disability), or both, and are used to assess the
presence or absence of disease and its consequences in these
terms. Such instruments include the Bath Ankylosing Spond-
ylitis Functional Index (BASFI)8; the Leeds Disability Ques-
tionnaire (LDQ)9; the Ankylosing Spondylitis Assessment
Questionnaire (ASAQ)10; the Dougados Functional Index
(DFI)11; a version of the Stanford Health Assessment
Questionnaire modified for the spondyloarthropathies (HAQ-
S)12; and, a modified version of the Arthritis Impact Measure-
ment Scales 2 specific to AS (AS-AIMS2).13 Although such
measures provide important information about the degree of
impairment and disability experienced by patients, they do
not inform on the impact of the condition on QoL. The
construct of QoL differs from impairment and disability
insofar as it concerns the impact of disease from the patient’s
(rather than a clinical) perspective. By investigating how
patient’s lives are affected by impairment, disability, and other
influences it provides an outcome that is complementary to
the traditionally assessed impacts of disease.14 15 Generic
health status instruments such as the Nottingham Health
Profile, Short Form-36 (SF-36), and EuroQoL also concentrate
on impairment and disability rather than QoL. Furthermore,
they have been shown to lack the responsiveness necessary to
detect real changes in health status associated with effective
treatment.8 16
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There is a clear need for a valid and reliable disease-specific
instrument for assessing the impact of AS on QoL that is suit-
able for use in clinical practice. This paper describes the devel-
opment of such a measure, the Ankylosing Spondylitis Qual-
ity of Life Questionnaire (ASQoL). The instrument was
required to be suitable for monitoring patients, evaluating
alternative treatment regimens, new pharmaceutical products
and/or models of service delivery from the patient’s percep-
tion. The development methodology employed is based on
recent advances in the recognition and understanding of the
conceptual and practical basis of measurement. The process
combines the theoretical strengths of the needs-based QoL
model17 with the statistical and diagnostic power of the Rasch
model.18 The needs-based model of QoL postulates that life
gains its quality from the ability of the individual to satisfy his
or her needs. QoL is high when these needs are fulfilled and
low when few needs are satisfied. The model is well
established and has been applied successfully in the develop-
ment of a large number of disease-specific QoL instruments,
several of which have become established as the preferred
outcome instrument for clinical trials and studies.17 19–26 Appli-
cation of the Rasch model ensures that the fundamental scal-
ing properties of the instrument (for example, unidimension-
ality and level of measurement) are assessed in addition to the
traditional psychometric assessments of reliability and con-
struct validity. Such basic measurement properties were con-
sidered at each stage of the development of the ASQoL.
PATIENTS AND METHODS
Figure 1 sets out the stages in the development of the ASQoL.
The intention was to produce an instrument that would be
equivalent for both the UK and the Netherlands (NL). Conse-
quently, all stages were conducted simultaneously in both
countries, with the exception of stage 4, which took place in
the UK only. The purpose of stage 4 was to produce a more
efficient instrument for final testing, by removing clearly
problematic items.
Patient samples
The study was approved by ethics committees in both countries
and participants gave their written informed consent. All par-
ticipating patients fulfilled the modified New York criteria for
AS.27 28 Patients with significant comorbidity such as psychiat-
ric disorders, cancer, or fibromyalgia were excluded. To ensure
that a wide spectrum of clinical features was represented, each
sample included patients with both axial and peripheral
disease, a range of disease duration, and patients with uveitis
or inflammatory bowel disease, or both. Patients were recruited
from three hospitals in the north of England and from three in
the south of the Netherlands. In both countries, different
patients participated at each stage of the study.
Stage 1: Interviews with patients
Deriving the content of a measure from subjects who are rep-
resentative of the target population ensures that only relevant
topics are included and that areas important to QoL are not
omitted. For the ASQoL, the content of the questionnaire was
derived from unstructured, qualitative interviews with rel-
evant patients in both countries, conducted by experienced
qualitative researchers. The interviews, took the form of infor-
mal, focused conversations. They were designed to explore the
impact of AS on the patient, with emphasis on the person’s
ability to fulfil his or her needs. For example, where
interviewees indicated functional limitations associated with
AS they were prompted to consider how such restrictions
impacted on their lives—particularly, how they prevented the
fulfilment of their needs. The interviews were audio recorded
with permission of the interviewee. Transcripts were produced
from the tapes, which were then wiped clean. All traces of the
interviewee’s identity were omitted from the transcripts to
maintain anonymity.
Stage 2: Selection of items and response format for the
draft questionnaire
In both countries, the interview transcripts were subjected to
independent content analysis to identify statements relating
to need satisfaction. As far as possible, the actual words used
by interviewees were selected for the questionnaire. Duplicate
and idiosyncratic items were removed and the list was
subjected to further scrutiny, with items retained if they were
applicable to all potential respondents, reflected a single idea,
were unambiguous, and were short and simple. The item lists
from each country were then compared at a meeting between
the English and Dutch researchers. The purpose of this meet-
ing was to decide on the content for the first draft of the ques-
tionnaire and to identify a response system that would be
suitable for both languages.
A yes/no response systemwas selected for the draft measure
as previous experience had indicated that this maximises lan-
guage equivalence and ease of scoring and minimises
respondent burden. In the development of the rheumatoid
arthritis-specific instrument (the RAQoL) it was shown that a
yes/no response format was more sensitive to change than a
four-response Likert-type format.22
Stage 3: Field testing for face and content validity
The purpose of this exercise was to test the applicability, com-
prehensibility, relevance, and comprehensiveness of the
ASQoL with patients with AS. Participants completed the
questionnaire in the presence of an interviewer. They were
then asked to comment on its ease of completion and on the
appropriateness of the instructions, items, and response
format. Items found to be problematic in either country were
removed. Items were considered problematic if respondents
found them ambiguous or difficult to understand. Results
Figure 1 Stages in production of the ASQoL
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from this stage were used to compile a second draft version of
the measure.
Stage 4: Postal survey 1 (UK)
The new draft ASQoL was sent by post to patients in the UK.
Analyses were performed on the resulting data in order to
identify items that failed to fit onto the underlying measure-
ment construct and/or that worked differently by age (above
or below the median), gender, AS diagnosis (axial only or axial
with peripheral involvement), or disease duration (above or
below the median). Such differential item functioning (DIF)
would indicate that an item is valued differently by subgroups
of patients. For example, in a disability measure it might be
suggested that an item such as “I am unable to travel to my
workplace” would be affirmed less often by respondents who
had reached retirement age. Therefore, regardless of their level
of disability, this item would appear to be less severe for
younger respondents. DIF was identified though the applica-
tion of the one parameter logistic item response theory
model—the Rasch model.18 In the context of a QoL scale, the
Rasch model applies the premise that the likelihood of a per-
son affirming a particular item depends on the level of QoL of
the person and on the level of QoL represented by that item.
The analysis provides estimates for the item and person
parameters in log-odds units (logits). Such estimates are
based on the assumption that the scale is indeed measuring a
single underlying construct—that is, that the items form a
unidimensional scale. The extent to which this assumption is
justified is indicated by item fit statistics. For the present
analysis, Rasch mean square (MNSQ) item fit statistics were
identified through application of the computer program
WINSTEPS.29 Two MNSQ statistics are given; an information-
weighted fit statistic (INFIT) and an outlier-sensitive fit
statistic (OUTFIT). OUTFIT is more sensitive to inconsisten-
cies in the extreme responses, that is those made to items far
removed from the individual person’s level of QoL. The INFIT
statistic is weighted so that these outliers have less impact and
is, thus, more sensitive to non-extreme responses. Taken
together, these two MNSQ item fit statistics provide infor-
mation on the extent to which the individual items map onto
the underlying measurement construct, in this case, the QoL.
Given the present sample sizes,MNSQ values between 0.7 and
1.3 were taken to reflect adequate fit to the model.30 As no
Dutch data were included in stage 4, only those items that
were clearly problematic were removed. The third draft of the
questionnaire was produced on the basis of these analyses and
used in the subsequent postal survey in both countries.
Stage 5: Postal survey 2 (UK and NL)
The purpose of the final postal survey was to assess the scal-
ing properties, reliability, internal consistency, and construct
validity of the ASQoL in each country. Patients in both coun-
tries were sent a package consisting of the ASQoL, a
demographic questionnaire, additional comparator measures,
and a reply paid envelope. Patients who completed and
returned the first pack were sent a similar package timed to
arrive two weeks later. The demographic questionnaire, which
was consistent across countries, included questions on patient
perceived disease activity and severity of illness. The Notting-
ham Health Profile (NHP)31 and the BASFI were used as com-
parator measures in both countries. In addition, the LDQ was
used in the UK and the DFI32 was selected in the Netherlands.
The NHP is a measure of perceived distress and provides a
profile of scores in six sections: physical mobility, energy level,
pain, emotional reactions, social isolation, and sleep. It is
scored out of a maximum of 100 for each of the sections, with
a higher score indicating greater distress. The BASFI, the LDQ,
and the DFI each yield a single score. Scores on the BASFI can
range from 0 to 100, on the LDQ, from 0 to 48, and on the DFI
from 0 to 40. For each of these scales, a high score indicates
greater disability. Each item on the ASQoL is given a score of
“1” or “0”. A score of “1” is given where the item is affirmed,
indicating adverse QoL. All item scores are summed to give a
total score or index, with a high score indicating a worse QoL.
Questionnaires with missing data were omitted from the
analysis. The following properties of the two versions of the
ASQoL were assessed: scaling properties, reliability, internal
consistency and construct validity.
Scaling properties
Rasch analyses were conducted to confirm that items mapped
onto the same underlying construct (unidimensionality), that
they represented different amounts of the construct (hierar-
chical ordering), and that they worked in same way across
different patient groups (DIF). The level of measurement (that
is, ordinal or interval level) provided by the measure was also
examined.
Reliability
The reliability of the ASQoL was assessed by the test-retest
method. This is an estimate of the instrument’s reproducibility
over time, assuming that no change in condition has taken
place. For each country, ASQoL scores from each administra-
tion were correlated. Patients were excluded from these
analyses if they reported significant changes to their perceived
general health, severity of illness, or perceived disease activity
(that is,whether or not the patients considered their disease to
be active at the time of completing the questionnaire) between
administrations. Where an instrument is required for use in a
clinical trial or for monitoring individual patients, a correla-
tion coefficient of at least 0.85 is required.33 Owing to the ordi-
nal nature of the data, Spearman rank correlation coefficients
were produced (intraclass correlation coefficients are also
reported for information only).
Internal consistency
Internal consistency was assessed by Cronbach’s α coeffi-
cients. This statistic indicates the degree of relatedness
between items. A value of 0.70 or above was taken as reflect-
ing adequate internal consistency.34
Construct validity
ASQoL scores were related to the comparator instruments and
to patient perceived general health and severity of illness and
patient perceived disease activity (that is, whether or not the
patients considered their disease to be active at the time of
completing the questionnaire). Patients describe disease
activity in terms of whether they are having a “good day” or a
“bad day”. This terminology is used throughout the “Results”
section. It was predicted that there would be a moderate
association between the ASQoL and the comparator measures
indicating that they assess different but related constructs. It
was also suggested that QoL would be worse for respondents
experiencing a bad day (active disease), those reporting poorer
general health, or those describing their AS as severe.
RESULTS
Findings from the interviews (stage 1)
Thirty patients were interviewed in the UK and 25 in the
Netherlands. Patient samples were comparable in each coun-
try. About two thirds of those interviewed were male and a
third reported having peripheral arthritis. The age of those
interviewed ranged from 18 to 78 years, with disease duration
ranging from 1.5 to 44 years. Interviews lasted for between 30
minutes and two hours with a median length of one hour and
10 minutes. All respondents chose to be interviewed in their
own homes and all gave consent for the interview to be audio
recorded.
Similar findings emerged from the Dutch and UK
interviews. Respondents commented on the impact of pain
22 Doward, Spoorenberg, Cook, et al
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and its effect on sleep, mood, motivation, and ability to cope
with the day ahead. One of the greatest fears expressed was
that of losing independence.Many reported that they required
some degree of assistance with everyday tasks such as dress-
ing, washing, and shopping (particularly for foodstuffs). In
addition, many reported feeling that they were no longer in
control of their own personal hygiene or grooming. A particu-
lar concern was about the future, especially in relation to
uncertainties surrounding disease progression.
The AS had a major impact on interviewees’ ability to meet
their needs for stimulation and exploration, gender role fulfil-
ment, and feelings of worth.Major impacts were also reported
on self image and self esteem, resulting from concerns about
appearing slouched or slovenly.
AS had a profound impact on relationships with family
members and friends, and social life was severely limited. For
example, several interviewees commented that they chose
places they could visit on the basis of how tolerable they found
the seating. The condition was often cited as a major source of
family tension and some interviewees reported taking out
their frustration and anger on those closest to them.
Development of the draft questionnaire (stage 2)
Items for the questionnaire consisted of actual quotations
from the transcripts in a majority of cases. However, it was
necessary to change the actual words used by interviewees for
some of the items. For example, some were shortened, had the
word order altered, or were changed so that they were
expressed in the first person and/or in the present tense. The
item pool from each country was compared and items selected
for the draft questionnaire that covered issues raised in both
countries. Forty one items were selected that best expressed
the issues raised by the interviewees.
Field testing for face and content validity (stage 3)
In the UK 10 patients were interviewed in clinic and 5 in their
home. In the Netherlands all 15 patients were interviewed in
clinic. The ASQoL took between two and 16 minutes to
complete (median four minutes in both the UK and NL). The
measure was well accepted by interviewees in both countries,
who generally found the items to be easily understood and rel-
evant. Field testing of the questionnaire resulted in minor
changes to the wording of two items and the removal of five
more from both language versions. Itemswere removed because
they were found to be problematic or were considered inappro-
priate by a number of respondents. For example, the item “I find
it difficult to get moving in the morning” was among those
deleted, as it was interpreted in different ways by UK respond-
ents. The item “I often have to rest when doing jobs around the
house” was removed because of gender bias. Although the item
was intended to cover a range of household tasks, such as cook-
ing, cleaning, decorating, or home maintenance, it was
generally construed by patients in the UK to be solely related to
housework.Manymale respondents in the UK commented that
they never undertook such tasks and, consequently, could not
answer the question. After these changes, a 36 item version of
the ASQoL was produced for use in the first postal survey.
Testing the psychometric and scaling properties of the
ASQoL
For both versions of the measure, a high score indicates worse
QoL. For all tables in the following sections, n values deviating
from the overall number are owing to individual missing
responses.
Results of the first postal survey (UK) (stage 4)
Questionnaire packs were distributed to 180 people and
returned by 121, a response rate of 67%. Table 1 shows the
demographic details of the sample. Rasch analyses were
performed on the data to identify items that were problematic
because of misfit or DIF. Although a number of items were
found to misfit, DIF was minimal. As a result of these
analyses, 10 items were removed from the measure, leaving a
26 item version of the ASQoL. This version was taken forward
for further testing in each country.
Table 1 Demographic and disease information (postal surveys). Results are shown
as No (%)
First postal survey
(stage 4)
UK (n=121)
Second postal survey (stage 5)
UK
(n=210)
The Netherlands
(n=154)
Demographic details
Men (%) 92 (76) 150 (72) 110 (71)
Women (%) 29 (24) 59 (28) 44 (29)
Age range (years) 21–77 19–82 20–79
Mean age (SD) (years) 47.6 (12.4) 46.1 (12.4) 47.6 (11.8)
Married or living as married (%) 85 (72) 144 (69) 126 (82)
Disease information
Range of duration of illness (years) 1.5–50 1–62 3–51
Median (mean) duration of illness in years 15 (16.3) 18 (19.6) 19 (20.8)
No reporting peripheral involvement (%) 85 (70) 174 (83) 112 (71)
No reporting uveitis (%) 30 (25) 48 (23) 36 (23)
No reporting IBD (%) 14 (12) 31 (15) 22 (14)
Perceived AS severity
Mild (%) 18 (15) 22 (11) 36 (25)
Moderate (%) 50 (42) 76 (37) 69 (47)
Quite severe (%) 45 (38) 93 (45) 35 (24)
Very severe (%) 5 (4) 16 (8) 6 (4)
Perceived general health status
Excellent/very good (%) 12 (10) 10 (5) 7 (5)
Good (%) 48 (39) 58 (28) 48 (32)
Fair (%) 43 (36) 100 (49) 83 (55)
Poor (%) 18 (15) 38 (18) 14 (9)
Perception of today
Very good (%) 11 (9) 11 (5) 13 (8)
Good (%) 71 (61) 101 (50) 95 (62)
Bad (%) 34 (29) 83 (41) 42 (27)
Very bad (%) 1 (1) 8 (4) 4 (3)
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Results of the second postal survey (stage 5)
In the UK, 288 questionnaires were distributed at time 1 and
210 were returned, a response rate of 73%. Of these, 157 (75%)
were returned at time 2. In the NL, 180 questionnaires were
distributed at time 1 and 158 were returned, giving a response
rate of 88%. Of these, 139 (88%) were returned at time 2. Four
questionnaire sets from the Dutch sample were returned too
late to be included in the analyses. Table 1 shows demographic
details of the samples at time 1 in the UK and the NL. It can
be seen from the table that the samples included in the postal
surveys were similar demographically. Demographic charac-
teristics of respondents at time 2 were also comparable. Table
1 also provides information on the respondents’ perceived
health status. The table shows that the UK respondents rated
their health status worse than the Dutch participants.
Respondents’ scores on the comparator instruments showed
that, with the exception of social isolation, perceived distress
(as shown by NHP section scores) is high for this patient sam-
ple and higher in the UK than in the NL (extra web table W1).
Rasch analyses were conducted on the data from each
country. Eight items were removed as they were shown to
misfit in one or both countries. The fit of the final 18 item
ASQoL was good in both countries, with most MNSQ values
within the required 0.7–1.3 range (table 2). Item stability over
time was excellent in both countries, with Rasch item param-
eter estimates similar at times 1 and 2 (within 95% confidence
intervals). Items were not equally spaced along the measure-
ment continuum, indicating that the 18 item ASQoL produces
raw scores at the ordinal level of measurement.
Scores on the 18 item ASQoL can range from 0 to 18.
Median scores for the UKwere 10.0 (interquartile range (IQR)
5.0–14.0;mean 9.5, standard deviation (SD) 5.3) at time 1 and
9.0 (IQR 4.0–14.0; mean 8.8, SD 5.7) at time 2. For the NL,
median scores were 6.0 (IQR 2.0–10.0; mean 6.7, SD 4.8) at
time 1 and 6.0 (IQR 1.5–9.0; mean 6.2, SD 4.8) at time 2. Rela-
tively few respondents scored at the extremes, although the
basement effect was greater in the NL.
Association with additional factors
ASQoL scores were not related to duration of illness or to the
presence of uveitis. Patients with inflammatory bowel disease
scored higher on the measure (indicating worse QoL) than
those without (UK p<0.01, NL p<0.005; Mann-Whitney U
test).
Reliability and internal consistency of the ASQoL
The Spearman rank correlation coefficient for the test-retest
reliability of the 18 item ASQoL was 0.92 in the UK (n=129)
and 0.91 (n=119) in the NL, indicating that the measure has
excellent reliability, producing low levels of random measure-
ment error. Identical intraclass correlation coefficients were
obtained (0.92 in the UK and 0.91 in the NL). Very few
patients (two in the UK and one in the NL) reported any sig-
nificant change in perceived general health, severity of illness,
or perceived disease activity. Therefore, removing such
patients made little difference to the results obtained. The
Table 2 Rasch item statistics for the 18 item ASQoL
in the UK and Netherlands
Item number
Mean square fit statistic (MNSQ)
UK Netherlands
INFIT OUTFIT INFIT OUTFIT
1 0.90 0.74 0.91 0.78
2 1.21 1.22 0.93 0.84
3 0.95 0.87 0.97 0.88
4 0.79 0.77 0.84 0.63
5 1.02 0.70 1.25 1.23
6 0.88 0.75 0.87 0.71
7 1.36 1.87 1.00 1.06
8 0.83 0.65 0.93 0.68
9 0.99 0.96 0.99 0.91
10 1.13 0.84 1.08 1.25
11 0.86 0.71 1.20 1.15
12 1.20 1.40 1.06 1.12
13 0.99 0.90 0.89 0.76
14 0.88 0.92 1.37 1.16
15 0.98 0.90 0.90 0.74
16 1.16 1.06 0.98 1.08
17 1.11 1.02 0.76 0.76
18 0.87 0.73 1.19 1.16
Bold italics, MNSQ values above 1.3; italics, MNSQ values below
0.7.
Table 3 Correlations* between scores on the 18
item ASQoL and those on the comparator measures
Comparator measure UK Time 1 Netherlands Time 1
NHP sections
Physical mobility 0.78 0.79
Energy 0.74 0.73
Pain 0.81 0.79
Emotional reactions 0.72 0.73
Sleep 0.54 0.59
Social isolation 0.53 0.50
BASFI 0.72 0.75
LDQ 0.70 –
DFI – 0.80
*Spearman rank correlation coefficients.
Table 4 ASQoL scores by specified groups
Grouping factor
UK Netherlands
n Median IQR n Median IQR
Disease activity (good day/bad day) p<0.001* p<0.001*
Very good/good 102 7.0 3.0–11.3 101 5.0 1.5–9.0
Very bad/bad 81 13.0 10.0–15.5 40 10.0 8.0–12.7
Perceived general health p<0.001** p<0.001**
Excellent/good 61 3.0 1.0–7.0 52 2.0 0–4.0
Fair 91 11.0 8.0–13.0 76 9.0 6.0–10.7
Poor 34 15.0 14.0–17.0 12 13.5 12.0–14.7
Perceived AS severity p<0.001** p<0.001**
Mild 19 3.0 1.0–5.0 34 1.5 0–4.2
Moderate 73 7.0 3.0–10.0 61 6.0 4.0–10.0
Quite/very severe 95 13.0 11.0–16.0 39 9.0 8.0–12.0
*Mann-Whitney U test; **Kruskal-Wallis one way analysis of variance.
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ASQoL also has good internal consistency in both countries
(0.91 at time 1 and 0.92 at time 2 in the UK and 0.89 at time
1 and 0.90 at time 2 in the NL).
Validity of the ASQoL
Evidence of construct validity was provided by examining the
levels of association between the ASQoL and the comparator
instruments. Moderate to high correlations were found
between the ASQoL and all the comparator instruments (table
3). The pattern of association between the NHP section scores
and the ASQoL was as expected, with the highest correlations
being with the physical mobility, pain, and energy level
sections. The correlations with the emotional reactions section
were also high. Further evidence of the validity of the ASQoL
was gained by investigating the measure’s ability to distin-
guish between specified groups of patients (known groups
validity). Table 4 shows that ASQoL scores differed signifi-
cantly by whether the respondent was having a good or a bad
day (disease activity), self perceived general health status, and
self perceived AS severity.
DISCUSSION
The efficient and cost effective management of any disease
requires competing treatment regimens to be evaluated for
their ability both to control the disease and improve the QoL of
patients. Existing instruments for use with subjects with AS
focus on symptoms and functioning. Although these provide
important information they do not provide information about
the overall impact of the condition and its treatment on the
patient’s QoL. The ASQoL is based on a clear, conceptual model
of the QoL that has been successfully employed in the
development of several other disease-specific QoL
instruments.17 19–26 The development process was conducted in
parallel in the UK and the NL. Consequently, it was possible to
remove items that were problematic in one or other language
version of the instrument at each stage of the testing
procedure. This method of development is preferable to the
standard one, in which an instrument is produced in one
country and then adapted for use in other languages. Such
sequential development cannot overcome cultural and lin-
guistic differences between countries.
The content of the measure was derived from interviews
with subjects diagnosed with AS in the UK and the NL. For
each language version, the items are expressed (as far as pos-
sible) in the original words of the patients. Consequently,
respondents find the instrument acceptable, comprehensive,
and relevant to their condition. The ASQoL is quick and easy
to complete (taking less than five minutes),making it suitable
for use in clinical settings.
Application of item response theory in the form of the one
parameter Rasch model showed that the ASQoL was
unidimensional, had good item stability over time, and had
minimal DIF. The reliability of each language version of the
measure has been shown to be excellent—the test-retest reli-
ability coefficients obtained indicate that the ASQoL is
suitable for use in routine clinical practice or for monitoring
the progress of individual patients. Internal consistency was
also adequate. It is essential to establish that a new
instrument has construct validity—that is, that it is measur-
ing the intended construct. Two prerequisites for this are that
the instrument is based on a model of the construct assessed
and that it has good reliability.35 These requirements were met
in both countries and hence, it is possible to infer that the
ASQoL provides a valid assessment of the construct defined in
the model. However, it is also necessary to determine
construct validity formally through association with instru-
ments measuring related constructs (convergent validity) and
by comparing scores of patients at different stages of disease
activity or with different disease severity (known groups
validity). For the ASQoL, formal assessment was undertaken
by correlating scores on the ASQoL with those on the NHP and
the BASFI. ASQoL scores in the UK were also correlated with
the LDQ and in the NL with the DFI. These comparator
instruments measure a range of constructs; the NHP assesses
perceived distress, whereas the BASFI, LDQ, and DFI measure
AS-specific disability. The relatively high levels of association
between the ASQoL and these different constructs reflect the
multifaceted nature of the impact of the disease on the
patient. For example, pain, being a prominent feature of AS,
would be expected to have a major influence on the QoL of the
patient and, indeed, the correlation between these two
measurements indicates approximately 66% shared variance.
Similarly, QoL was moderately highly correlated with physical
disability, energy, and emotional reactions sections of the NHP.
The results obtained show that the ASQoL and comparator
instruments measure different though related constructs.
Taken together, they provide a more complete picture of the
impact of AS than any single measure can give alone.
The psychometric and scaling properties of the ASQoL sug-
gest that researchers and clinicians can have confidence in the
scores obtained by respondents on the measure. Further
assessments of the instrument’s validity will be possible as it
is used in clinical studies. In addition, it is recommended that
future studies are carried out to assess responsiveness, the
instruments ability to detect meaningful changes in QoL.
The decision to adopt a dichotomous response system for
the instrument was driven by practical issues related to
language equivalence and ease of completion and scoring.
There is often an assumption that such simplification is at the
cost of some loss of sensitivity because it is presumed that
multiple response items are able to provide more detailed
information about the variable of interest. However, this
assumption is not necessarily correct.22 The ASQoL comprises
18 dichotomous items that have been shown through Rasch
analysis to form a single scale. Furthermore, the results from
the assessment of known groups validity suggest that this
scale can measure the QoL associated with a wide range of
perceived disease severity and activity.
The ASQoL will serve as a valuable tool for assessing the
impact of AS and its treatment on QoL in clinical settings and
research studies. Such an instrument will allow accurate
assessment of the effectiveness of interventions from the
patient’s perspective.
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